NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) Stock Analysis

Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

FBIOP

$18.75

+$0.19 (+1.02%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare FBIOP with… →

FBIOP Key Statistics

As of Sep 4, 2026
Trading
Open
$18.55
Previous Close
$18.56
Day's Range
18.54–18.80
52-Week Range
6.27–21.43
Volume
7.80K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.19
Valuation
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.86
Financials (FY)
Revenue (FY)
$63.26M+9.69%
Net Income (FY)
$6.82M
Profit marginThe share of revenue left as profit after all costs and taxes.
163.32%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
56.68M
1-Year Return
+114.53%
Dividend and dates
Avg Volume
13.90K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

FBIOP Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+97.58%
2025+42.71%
2024−39.63%
2023−21.91%
2022−23.80%
2021+46.76%
2020+7.70%
2019+59.74%
2018−28.90%
2017 (partial year)−6.19%

As of September 4, 2026.

FBIOP Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$63.26M$6.82M10.8%
2024$57.68M−$46.00M−79.8%
2023$84.51M−$60.64M−71.7%
2022$75.74M−$86.58M−114.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$63.26M$42.34M−$70.22M$6.82M10.8%
2024$57.68M$36.80M−$111.24M−$46.00M−79.8%
2023$84.51M$61.62M−$139.20M−$60.64M−71.7%
2022$75.74M$44.97M−$203.56M−$86.58M−114.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

FBIOP Valuation vs Biotechnology Median

Median of 656 stocks
MetricFBIOPBiotechnology medianvs median
Profit margin163.32%0.00%163.3 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock trades under the ticker FBIOP. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 78.

FBIOP last closed at $18.75 on September 4, 2026. That is +$0.19 (+1.02%) against the previous close. The 52-week range on file runs from $6.27 to $21.43. The latest close sits 199.04% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $63.26M. That is +9.69% against the prior fiscal year, when revenue was $57.68M. The same year closed with net income of $6.82M. Profit margin runs at 163.32%. That is 163.3 percentage points above the Biotechnology median of 0%. Trailing earnings per share are −0.86.

Across the 4 fiscal years on file, revenue moves from $75.74M in 2022 to $63.26M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Beta against the wider market is reported at 1.19. Annualized volatility over the trailing 8 years is 52.35%. Over the trailing twelve months the price has returned +114.53%. Measured over 5 years, that is +0.85% a year compounded.

Growth & Income

The record shows no dividend for FBIOP.

Across the complete calendar years on file, 2019 returned +59.74% and 2024 returned −39.63%. Of the 8 complete calendar years on file, 4 finished higher. 2026 is still running; the price is +97.58% year to date.

Peer Comparison

Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock FBIOP — —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma. It also develops CUTX-101, a copper histidinate injection, which is in FDA approved stage for the treatment of Menkes disease; IV Tramadol, an intravenous formulation, which is in NDA/BLA filed stage for the treatment of post-operative acute pain; Dotinurad, a urate transporter inhibitor, which is in Phase III for the treatment of gout and chronic kidney diseases; CAEL-101, a light chain fibril-reactive monoclonal antibody, which is in Phase III for the treatment of amyloid light chain amyloidosis; and Triplex, a universal recombinant modified vaccinia ankara viral vector vaccine, which is in Phase II for the treatment of cytomegalovirus, anti-human immunodeficiency virus, non-hodgkin lymphoma, and acute lymphoblastic leukemia. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Visit website →